AI Article Synopsis
- Drug resistance in organisms like cancer cells, bacteria, and fungi poses a significant challenge for treating human diseases, particularly with anticancer drugs, antibiotics, and antifungals.
- Strains of Candida resistant to azole antifungal drugs, commonly seen in HIV patients after using prophylactic azole treatments like fluconazole, highlight the need to monitor drug-resistant infections.
- The review focuses on the molecular mechanisms that contribute to resistance against azole and candin antifungal agents, emphasizing the importance of understanding these mechanisms for developing effective treatments.
Article Abstract
Drug resistance in various organisms including cancer cells, bacteria and fungi is a serious issue for human disease therapy, including use of anticancer drugs, antibiotics and antifungals, respectively. Candida strains resistant to the azole class of antifungal drugs, have been isolated frequently from HIV patients following prophylaxis with azole drugs such as fluconazole. Therefore, it is important to be aware of the emergence of drug-resistant clinical isolates, despite the recent introduction of new, effective classes of antifungal drugs such as the azole voriconazole, and the candin micafungin. In this review we discuss the molecular mechanisms underlying resistance to the azole and candin antifungal agents.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!